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Objectives: Although the fracture risk assessment tool (FRAX) developed by WHO 
is considered to be valid and reliable, its algorithm is not open to the public and is 
thus unavailable for economic evaluations. The purpose of this study was to develop 
a state transition model with risk equations for osteoporotic fracture in Japanese 
women and to verify the validity of our model by comparison of the predicted 
10-year osteoporotic fracture probabilities in our model and those derived from 
the FRAX. MethOds: Equations for age and femoral neck BMD specific incidence 
of hip, clinical spine, and other fracture were developed using a series of methods 
by De Laet, et al and epidemiological data of postmenopausal Japanese women. A 
patient-level state transition model with ten health states using the equations was 
used to predict the 10-year probability of a hip fracture and a major osteoporotic 
fracture in Japanese women with osteoporosis, who had no treatments. We ran 
the model with different combinations of BMD (T-score−1.5, −2.0, or −2.5), and the 
number of clinical risk factors (0, 1, 2, or 3). The predicted values in our model were 
compared with those of the FRAX. Results: For 70-year-old women with differ-
ent combinations of T-scores and the number of clinical risk factors, the estimated 
10-year probabilities of hip fracture in our model were almost identical to those 
of the FRAX. The 10-year probabilities of major osteoporotic fracture in our model 
also appeared to be consistent with those of the FRAX. These findings supported 
the validity of our model in the use of health economic evaluation. cOnclusiOns: 
The developed model appears to be a valid model for use in economic evaluation in 
osteoporosis from the perspective of Japan healthcare system. The relation between 
10-year fracture probability and ICER of osteoporosis treatment can be estimated 
using this model.
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Objectives: To develop and validate a conceptual model (CM) of multiple myeloma 
(MM) for use in economic modelling that characterises the disease in terms of 
attributes that impact on disease progression and outcomes. MethOds: A draft 
CM was developed using two systematic literature reviews to identify attributes of 
MM that appeared to impact on disease progression and outcomes. These attributes 
were grouped according to the aspects they measured (e.g. symptoms) and then 
linked to denote relationships across groups. This was discussed and validated 
by a Delphi panel of four MM experts. For simplicity, the CM did not consider the 
impact of treatment Results: Consensus was reached about the attributes to be 
included in the CM: baseline and disease characteristics (age, comorbidities, Eastern 
Cooperative Oncology Group performance status and genetic factors), central 
associations (disease activity, complications and symptoms) and final outcomes 
(overall survival [OS], quality of life). Disease activity was measured by several fac-
tors, including M-protein and serum lactate dehydrogenase. There was consensus 
that most genetic factors [e.g. t(4;14), del(13p)] influenced disease activity, which 
in turn affected complications (e.g. anaemia, renal complications). Symptoms (e.g. 
pain, bone fractures) were influenced by genetic factors and disease activity. Disease 
activity, comorbidities and complications impacted on OS. Consensus was not 
reached for the impact of age/comorbidities on complications/symptoms, nor for 
the influence of del(17p) on complications. cOnclusiOns: There was agreement on 
the attributes that should be used to characterise and understand MM; however, the 
lack of consensus on the association between some attributes reflects the relatively 
limited understanding of how aspects of MM impact on disease progression and 
outcomes. Future studies should focus on understanding the gaps identified. This 
CM may be used in economic modelling and could form the foundation for devel-
oping disease-based MM models to explore the impact of treatment on outcomes.
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Objectives: With a variety of medical technologies under development to 
address the increasing prevalence of Alzheimer’s Disease (AD) and Mild Cognitive 
Impairment (MCI), stakeholders need methods to assess and compare their value. 
The Clinical Dementia Rating (CDR) Sum of Boxes (SOB) scale can be used to stage 
AD and MCI severity, but has not previously been incorporated into cost-effective-
ness analysis (CEA) models. We developed a CEA framework to evaluate effective-
ness using the increasingly common CDR-SOB endpoint. MethOds: A systematic 
literature review was conducted to identify published AD and MCI cost-effective-
ness models. The review identified no models that evaluated effectiveness using 
the CDR-SOB score. To facilitate use of this measure in future health economic 
evaluations, we developed a state-transition model that synthesizes prior study 
results to link CDR-SOB score changes to MMSE health states. We then applied 
standard health state utilities and direct medical expenditure values from prior 
AD and MCI CEAs. Results: We mapped CDR-SOB scores to MMSE health states 
using the results from Delor et al. (2013) and O’Bryant et al. (2008), and extrapolated 
long-term (5+ year) disease progression using a variety of curve fits. Based on the 
baseline CDR-SOB score distribution, patients were assigned to one of five health 
of economic modelling (e.g. cycle length), these estimates cannot be incorporated 
directly. The objective was to adapt the remission rates to model cycle length, using 
various statistical methods. MethOds: From a systematic review, 4 studies reporting 
proportions of patients undergoing remission at different time points were identified. 
One of the studies reported data for 2 populations (CSU/CIU and all chronic urticaria 
patients), therefore, 5 populations were considered in total. A four-step approach 
was undertaken: (1) converting reported data to standard time units; (2) using the 
extracted data to run the Kaplan-Meier (K-M) analysis; (3) applying four statistical 
distributions (exponential, log-normal, weibull and log-logistic) to identify the distri-
bution best fitting the literature estimates. Lowest Kolmogorov-Smirnov (KS) distance 
was chosen as the criterion for the best fit distribution; (4) values obtained from the 
best fit distribution were further converted into rates for each 4-week cycle length. 
The analysis was carried out for 78 years to correspond to the lifetime horizon of the 
cost-effectiveness model. Results: Based on the KS distance, log-normal distribu-
tion was the best fit for 2 populations and log-logistic for 3 populations. Remission 
rates were generated for these 5 populations which ranged from 9.5% to 37.7% for 
year 1, 29.5% to 70.8% for year 5 and 49.6% to 91.5% for year 20. cOnclusiOns: This 
approach provides a robust statistical method for adapting the literature estimates 
as per the requirements of an economic model. Due to the wide range of remission 
estimates in the literature, face validation via expert clinical opinion is recommended 
to determine appropriate model inputs.
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Objectives: Functional dyspepsia or gastrointestinal disorders are extremely com-
mon in Germany. Estimates suggest that a total of 15-30% of adults suffer from func-
tional disorders. The aim of this study was to identify and weight the decision expert’s 
relevant decision criteria with regard to the drug treatment of functional dyspepsia 
or motility disorders. Attributes such as onset of action, reduction of symptoms and 
side effects were to be examined in order to test their relevance to health care deci-
sion makers. MethOds: On the basis of a literature search and qualitative patient 
(N= 6) and expert interviews (N= 4), a questionnaire was developed. By means of the 
analytic hierarchy process (AHP), the study elicited the priorities regarding various 
aspects of treatments of dyspepsia and motility disorders. The collection of data 
from experts of the field of gastroenterology was done in real time within the con-
text of a group discussion using an item-response-system. Results: As a result of 
the interviews, seven characteristics were established which were judged to be the 
most important. A total of N= 20 experts took part in the group discussion and the 
AHP survey. For all participants the criterion “reduction of abdominal cramps” was 
the most important attribute of a drug treatment. It became clear that reduction of 
symptoms, time to onset of action and risk of side-effects were of central importance. 
Consequently, the following criteria were assessed to be most relevant: reduction of 
abdominal cramps (w:0.302), reduction of epigastric pain (w:0.250) and time to onset 
of action (w:0.117). cOnclusiOns: The AHP represents a suitable and scientifically 
transparent approach for the elicitation of experts’ priorities within the context of 
group discussions. The item response system served as a valuable instrument to 
collect quantitative data based on a group discussion. The patient perspective in a 
subsequent discrete-choice experiment will expand the findings of this study.
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Objectives: Demonstrating face validity in health economic models enhances 
their credibility and is important if the model’s output is to robustly inform health-
care decision-making. Type 2 diabetes (T2DM) models are typically complex and 
their results are influenced by multiple factors including treatment effects, cohort 
characteristics, choice of rescue therapies and structural settings, such as ther-
apy escalation thresholds. The objective of this study was to illustrate the impact 
that baseline HbA1c and HbA1c trajectories exerts on time to therapy escalation 
when using guideline therapy escalation thresholds compared with clinical prac-
tice. MethOds: Using the UKPDS 68 HbA1c trajectory equation implemented within 
the IMS CORE diabetes model, the time to therapy escalation was assessed as a 
function of baseline HbA1c (7.0%, 7.5%, 8.0% and 8.5%) with therapy escalation 
thresholds recommended by NICE (7.5%) versus those observed in clinical practice 
in the UK (8.5%). Published data informed initial HbA1c treatment effects of -0.93% 
(standard deviation 0.17%). Second order uncertainty was utilised with baselines 
HbA1c, treatment reduction and HbA1c trajectories sampled; results were averaged 
over 10,000 simulations. Results: Using NICE escalation criteria (7.5%) mean (SD) 
time to escalation was 6.6 (0.6), 5.2 (0.5), 3.6 (0.5) and 1 (0.0) years for cohorts with 
baseline HbA1c of 7.0%, 7.5%, 8.0% and 8.5% respectively. Using escalation levels 
observed in clinical practice (8.5%) mean (SD) time to escalation was 17.4 (4.3), 14.0 
(3.2), 11.2 (2.4) and 8.9 (1.9) years for cohorts with baseline HbA1c of 7.0%, 7.5%, 
8.0% and 8.5% respectively. cOnclusiOns: The use of aspirational guideline based 
therapy escalation thresholds has the potential to significantly impact the expected 
time to therapy escalation and the variability in timing. As duration on therapy is 
a key driver in cost effectiveness studies, parameters controlling timing of therapy 
escalation should be robustly explored in sensitivity analysis.
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32.5% oncology, 17.5% auto-immune, 15% cardiovascular, 10% neurology/mental 
health, 5% infectious, 5% diabetes, and 15% other. Modeling techniques included 
discrete event simulation (12%), individual state-transition (15%) and most com-
monly state transition with tracking states. In most cases treatment sequencing 
was modeled to reflect clinical practice or clinical trial design. Other reasons 
included assessing where in a treatment sequence the new treatment belongs 
or evaluating the addition of more efficacious treatment options to the current 
treatment sequence. Efficacy inputs were generally based on trials that consid-
ered a single intervention and not a treatment sequence. Efficacy was commonly 
assumed to be the same regardless of line of therapy. Disease-related costs and 
utilities were mostly determined by disease status or its related events, and only 
seldomly by line of therapy. cOnclusiOns: Capturing treatment sequences in 
economic models is important for informing reimbursement, policy and clini-
cal decisions. Key considerations for determining how to best model sequences 
include: the number of treatment options, patient heterogeneity, key outcome 
events and event risk (time-varying or constant). A key challenge to model treat-
ment sequences is the scarcity of the clinical data as clinical trials do not com-
monly study sequences.
PRM95
BuDget iMPaCt analysis of CeReBRolysin in the tReatMent of aCute 
isCheMiC stRoke of MoDeRate anD seveRe DegRees of seveRity in the 
Russian feDeRation
Kulikov A, Abdrashitova G
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To conduct budget impact analysis of neurotrophic and neuropro-
tective drug cerebrolysin with standard therapy compared to standard therapy 
only of ischemic stroke of moderate and severe degrees of severity according to 
the Russian healthcare system. MethOds: The one year budget impact analy-
sis was conducted. We used the pharmacoeconomic analysis method – budget 
impact analysis and analysis of the direct and indirect costs. For reference, 
we accepted the exchange rate was 1 EUR = 60,64 RUB. Results: Direct costs 
include the cost of pharmacotherapy cerebrolysin, the cost of medical emergen-
cies, inpatient and outpatient - polyclinic medical care, as well as the cost of 
early neurorehabilitation, and indirect costs - the loss of gross domestic product 
as a result of disability and death, payments for sick leave and disability cost. 
As a result, the overall costs of standard treatment with cerebrolysin totaled 
378 278 RUB (6238 EUR); while the cost to standard therapy was 457 981 RUB 
(7552 EUR). Reducing the direct and indirect costs was obtained in the treatment 
group of cerebrolysin, because of lower mortality and reduce days of hospital 
stay compared with the standard therapy. cOnclusiOns: The results of budget 
impact analysis showed that the inclusion of cerebrolysin in standard therapy of 
ischemic stroke of moderate and severe degrees of severity can reduce the over-
all cost of the Russian health care system at 79 703 RUB (1314 EUR) per patient 
per year.
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Objectives: To compare methods for extrapolating survival curves for previ-
ously-untreated patients receiving nivolumab versus ipilimumab for BRAF wild-
type advanced melanoma (AM, comprising unresectable Stage III and/or Stage IV 
metastatic melanoma). MethOds: Patient-level data from 203 patients with AM 
receiving nivolumab in a phase III study (nivolumab versus dacarbazine) were used 
to estimate hazards of progression and death. Of these, 56.2% (n= 114) progressed 
and 23.2% (n= 47) died during the study period. Weibull, log-logistic and a Weibull 
mixture cure model (MCM) were fitted to extrapolate trial data for overall survival 
(OS) and progression-free survival (PFS) up to a 10 year time horizon. To estimate 
transition probabilities for subjects receiving ipilimumab, hazard ratios were cal-
culated by indirect comparison of nivolumab versus ipilimumab and applied to 
underlying survival distributions. Models were evaluated graphically, using Akaike’s 
Information Criterion (AIC) and naive comparison of the extrapolated ipilimumab 
survival functions with published long-term survival data. Results: AIC scores for 
the Weibull, log-logistic and MCM were 336.47, 335.30 and 776.20 for OS, respectively. 
The equivalent AIC scores for PFS were 511.39, 479.38 and 1421.63. The estimated 
3-year survival rate of patients receiving ipilimumab was 2.8%, 15.1% and 55.8% 
and 14.9%, 40.2% and 87.2% for patients receiving nivolumab using the Weibull, log-
logistic and MCM, respectively. This compares with published data showing approxi-
mately 21% (95% CI: 17-24%) of AM patients receiving ipilimumab (3 mg/kg) survive 
three years. Due to the short follow-up period for this study, the MCM introduced 
the greatest potential for error. cOnclusiOns: The log-logistic model provided 
the closest approximation to real-world ipilimumab data. The choice of parametric 
model exerts a large effect on predicted effectiveness and cost-effectiveness of 
new therapies and needs justification. Different models should be considered in 
sensitivity analyses to estimate their impact on ICERs.
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bAckgROund: The health consequences attributed to cigarette smoking and sec-
ondhand smoke exposure have been studied in many countries. Nevertheless, the 
economic burden of smoking, especially focusing on secondhand smoke is rarely 
dealt with. Objectives: To examine economic and health outcomes of secondhand 
smoking in Korea MethOds: We reviewed previous studies which demonstrated the 
states (preclinical, MCI, mild, moderate, or severe AD). Patients’ rate of progres-
sion through the health states was based on a weighted average of rates among 
‘slow’ and ‘fast’ progressing patients (derived from the AD neuroimaging initia-
tive). Each state has unique utility and expenditure impacts. This lifetime horizon 
model tracks AD progression, life years, quality-adjusted life years, and expendi-
ture. cOnclusiOns: This new framework provides a relatively simple and flexible 
way for users to simulate long-term AD and MCI health outcomes and assess the 
comparative effectiveness of strategies using a common trial endpoint.
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Objectives: When conducting an economic evaluation, it is important to select an 
appropriate model type and provide a justification. Many analyses utilise Markov 
models but these are associated with a number of limitations. Discrete Event 
Simulation (DES) models, in which events are estimated using discrete time inter-
vals rather than regular cycles and patients are simulated individually rather than 
as a cohort, can overcome many of the Markovian limitations. The aim of this study 
was to assess the advantages and disadvantages of DES and Markov models; utilis-
ing an application to HIV. MethOds: A systematic literature review was conducted 
to identify modelling approaches assessing the cost-effectiveness of HIV treatments. 
Additionally, the use of DES models within Health Technology Assessments (HTA) 
was evaluated. A de novo DES was developed in Microsoft Excel® with VBA, based 
on assumptions and data from an existing cost-effectiveness Markov model assess-
ing HIV treatments. Results: Of the HIV publications identified, 4% used a DES 
and 42% used a Markov model. Only 17% provided a discussion around their choice 
of model type. DES models have not yet been used in HTAs for HIV in the UK but 
nine were identified within other disease areas. The de novo DES and those in the 
published literature demonstrated a realistic modelling approach due to the dis-
crete timing of events and accounting for patient heterogeneity. The DES is a flex-
ible model which can accommodate future adaptations; however, it relies heavily 
on data requirements in order to maximise its potential benefit. cOnclusiOns: 
Neither Markov models nor DES are superior; the key is to choose the most suit-
able model for the decision problem and provide a clear rationale. In the context of 
HIV, DES is likely to be a good choice of model providing sufficient data is available.
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Objectives: We demonstrate an approach to select evidence-based preventive treat-
ment thresholds by optimizing preferred outcomes illustrated with a study on preven-
tive statin treatment based on 10-year coronary heart disease (CHD) risk predicted 
by the Framingham risk score (FRS). MethOds: A Markov decision-analytic model 
was used to simulate cohorts following usual care; preventive statin treatment in 
high-risk (FRS≥ 20%) individuals (ATPIII guideline), or, alternatively, an explorative 
approach of lowering treatment threshold T from 20.0% to 0.0% with 0.5% decre-
ments. A population-based cohort (n= 11,649) was used to recalibrate the FRS and 
calculate the distribution of individuals over the low (< 0.5T%), intermediate (0.5T%-
T%), and high (≥ T%) risk category and corresponding observed CHD risks. Treatment 
complications, quality-adjusted life-years (QALYs), and Net Health Benefit (NHB) 
(willingness-to-pay of $50,000/QALY) were evaluated. Uncertainty was assessed 
through probabilistic sensitivity analysis. Furthermore, we assessed the balance 
between additional individuals treated and additional health benefits when incre-
mentally lowering the threshold. Results: Over a 30-year time horizon, QALYs in 
men ranged from 12.679 at T= 20.0% to 12.752 at T= 0.0%, with a maximum of 12.753 
at T= 1.5%. For women QALYs ranged from 13.474 at T= 20.0% to 13.587 at T= 0.0%, with 
a maximum of 13.589 at T= 1.5%. Lowering the threshold monotonically increased 
costs, whereas the incremental NHB was favorable for every T< 20%. Incrementally 
lowering the threshold and comparing outcomes to the former threshold, for men and 
women marginal health effects achieved a maximum at T= 10.0%, whereas marginal 
costs were highest at T= 1.0% for men and T= 2.5% for women. The marginal NHB was 
favorable down to T= 2.0% for men and T= 3.5% for women. cOnclusiOns: Risk-
stratified prevention is increasingly recommended, while current intuition-based 
treatment threshold selection leaves ample room for health gain and cost-savings. 
Evidence-based selection, including estimation of long-term (marginal) health effects 
and costs, is essential, whether the goal is to maximize health outcomes or optimize 
cost-effectiveness.
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Objectives: As interventions available in a therapeutic area increase, the relevant 
decision question in health technology assessment (HTA) expands to include iden-
tifying the optimal treatment sequences or position for a treatment in a sequence. 
This study reviewed economic models capturing treatment sequences published 
by National Institute for Health and Care Excellence (NICE). MethOds: Economic 
models including a treatment sequence assessed by NICE were reviewed as these 
HTAs generally provide comprehensive detail on modeling. The rationale for 
modeling a sequence, modeling technique used, and approach to characterizing 
clinical, cost and utility impacts were evaluated. Results: Forty models were 
identified that considered treatment sequences in the following therapeutic areas: 
